Subscribe to RSS
DOI: 10.1055/s-0043-118910
Effects of Zinc Alpha2 Glycoprotein on Lipid Metabolism of Liver in High-Fat Diet-Induced Obese Mice
Publication History
received 18 May 2017
accepted 22 August 2017
Publication Date:
21 September 2017 (online)
Abstract
Zinc alpha2 glycoprotein (ZAG) is a new type of adipokine involved in adipose tissue mobilization, however, little is known about its lipid metabolism effect in liver. Therefore, we investigated the effects of ZAG in the regulation of hepatic lipid accumulation. Mice were randomly divided into two groups; one was fed a normal diet and another was fed a high-fat diet for eight weeks to establish obesity model. After that, the normal diet group was divided into ND (injection of pcDNA3.1) and NDZ (injection of ZAG recombinant plasmid) and the high-fat diet group was divided into HF (injection of pcDNA3.1) and HFZ (injection of ZAG recombinant plasmid). The mice were weighed once per week and injected with plasmid once every three days for eight times. The results showed that body weight and hepatic TG content were decreased dramatically in HFZ group compared with HF group. The stearoyl-CoAdesaturase1 (SCD1) and Acyl-CoA Synthetase-1 (ACSS1) protein levels in HFZ group were significantly decreased. Furthermore, phosphorylated hormone sensitive lipase (P-HSL) was significantly higher in HFZ group. In HFZ group, hepatic fatty acid translocase (CD36) and fatty acids binding protein-1 (FABP1) protein levels were reduced. In addition, the expression of phosphorylated protein kinase A (PPKA) in HFZ group was higher than the HF group. Meanwhile, NDZ group showed significantly decreased body weight and increased P-HSL level though the hepatic TG content showed no significantly changes compared with the ND group. Therefore, we conclude that ZAG may be beneficial for preventing high-fat-diet-induced hepatic lipid metabolic disorders.
-
References
- 1 Lakshmanan MR, Muesing RA, Cook GA, Veech RL. Regulation of lipogenesis in isolated hepatocytes by triglyceride-rich lipoproteins. J Biol Chem 1977; 252: 6581-6584
- 2 Kanuri G, Bergheim I. In vitro and in vivo models of non-alcoholic fatty liver disease (NAFLD). Int J Mol Sci 2013; 14: 11963-11980
- 3 Fabbrini E, Sullivan S, Klein S. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology 2010; 51: 679-689
- 4 Sanyal AJ. Mechanisms of Disease: pathogenesis of nonalcoholic fatty liver disease. Nat Clin Pract Gastroenterol Hepatol 2005; 2: 46-53
- 5 Roden M. Mechanisms of disease: hepatic steatosis in type 2 diabetes–pathogenesis and clinical relevance. Nat Clin Pract Endocrinol Metab 2006; 2: 335-348
- 6 Diez-Itza I, Sanchez LM, Allende MT, Vizoso F, Ruibal A, Lopez-Otin C. Zn-alpha 2-glycoprotein levels in breast cancer cytosols and correlation with clinical, histological and biochemical parameters. Eur J Cancer 1993; 29A: 1256-1260
- 7 Abdul-Rahman PS, Lim BK, Hashim OH. Expression of high-abundance proteins in sera of patients with endometrial and cervical cancers: Analysis using 2-DE with silver staining and lectin detection methods. Electrophoresis 2007; 28: 1989-1996
- 8 Tada T, Ohkubo I, Niwa M, Sasaki M, Tateyama H, Eimoto T. Immunohistochemical localization of Zn-alpha 2-glycoprotein in normal human tissues. J Histochem Cytochem 1991; 39: 1221-1226
- 9 Todorov PT, McDevitt TM, Meyer DJ, Ueyama H, Ohkubo I, Tisdale MJ. Purification and characterization of a tumor lipid-mobilizing factor. Cancer Res 1998; 58: 2353-2358
- 10 Russell ST, Zimmerman TP, Domin BA, Tisdale MJ. Induction of lipolysis in vitro and loss of body fat in vivo by zinc-alpha2-glycoprotein. Biochim Biophys Acta 2004; 1636: 59-68
- 11 Tzanavari T, Bing C, Trayhurn P. Postnatal expression of zinc-α2-glycoprotein in rat white and brown adipose tissue. Mol Cell Endocrinol 2007; 279: 26-33
- 12 Ceperuelo-Mallafré V, Näf S, Escoté X, Caubet E, Gomez JM, Miranda M, Chacon MR, Gonzalez-Clemente JM, Gallart L, Gutierrez C, Vendrell J. Circulating and Adipose Tissue Gene Expression of Zinc-α2-Glycoprotein in Obesity: Its relationship with adipokine and lipolytic gene markers in subcutaneous and visceral fat. J Clin Endocrinol Metab 2009; 94: 5062-5069
- 13 Gong FY, Zhang SJ, Deng JY, Zhu HJ, Pan H, Li NS, Shi YF. Zinc-α2-glycoprotein is involved in regulation of body weight through inhibition of lipogenic enzymes in adipose tissue. Int J Obes 2009; 33: 1023-1030
- 14 Mracek T, Ding Q, Tzanavari T, Kos K, Pinkney J, Wilding J, Trayhurn P, Bing C. The adipokine zinc-α2-glycoprotein (ZAG) is downregulated with fat mass expansion in obesity. Clin Endocrinol 2010; 72: 334-341
- 15 Mracek T, Stephens NA, Gao D, Bao Y, Ross JA, Rydén M, Arner P, Trayhurn P, Fearon KCH, Bing C. Enhanced ZAG production by subcutaneous adipose tissue is linked to weight loss in gastrointestinal cancer patients. Br J Cancer 2011; 104: 441-447
- 16 Tisdale MJ. Zinc-alpha2-glycoprotein in cachexia and obesity. Curr Opin Support Palliat Care 2009; 3: 288-293
- 17 Russell ST, Tisdale MJ. Studies on the anti-obesity activity of zinc-alpha2-glycoprotein in the rat. Int J Obes (Lond) 2011; 35: 658-665
- 18 Russell ST, Tisdale MJ. Studies on the antiobesity effect of zinc-α2-glycoprotein in the ob/ob mouse. Int J Obes 2010; 35: 345-354
- 19 Selva DM, Lecube A, Hernandez C, Baena JA, Fort JM, Simo R. Lower zinc-alpha2-glycoprotein production by adipose tissue and liver in obese patients unrelated to insulin resistance. J Clin Endocrinol Metab 2009; 94: 4499-4507
- 20 Jia Y, Cong R, Li R, Yang X, Sun Q, Parvizi N, Zhao R. Maternal low-protein diet induces gender-dependent changes in epigenetic regulation of the glucose-6-phosphatase gene in newborn piglet liver. J Nutr 2012; 142: 1659-1665
- 21 Bing C, Mracek T, Gao D, Trayhurn P. Zinc-α2-glycoprotein: an adipokine modulator of body fat mass?. Int J Obes 2010; 34: 1559-1565
- 22 Zhu HJ, Ding HH, Deng JY, Pan H, Wang LJ, Li NS, Wang XQ, Shi YF, Gong FY. Inhibition of preadipocyte differentiation and adipogenesis by zinc-alpha2-glycoprotein treatment in 3T3-L1 cells. J Diabetes Investigat 2013; 4: 252-260
- 23 Ge S, Ryan AS. Zinc-alpha2-glycoprotein expression in adipose tissue of obese postmenopausal women before and after weight loss and exercise + weight loss. Metab Clin Exp 2014; 63: 995-999
- 24 Frühbeck G, Méndez-Giménez L, Fernández-Formoso J-A, Fernández S, Rodríguez A. Regulation of adipocyte lipolysis. Nutr Res Rev 2014; 27: 63-93
- 25 Han YS, Arroyo J, Ogut O. Human heart failure is accompanied by altered protein kinase A subunit expression and post-translational state. Arch Biochem Biophys 2013; 538: 25-33
- 26 Balaz M, Vician M, Janakova Z, Kurdiova T, Surova M, Imrich R, Majercikova Z, Penesova A, Vlcek M, Kiss A, Belan V, Klimes I, Olejnik J, Gasperikova D, Wolfrum C, Ukropcova B, Ukropec J. Subcutaneous adipose tissue zinc-alpha2-glycoprotein is associated with adipose tissue and whole-body insulin sensitivity. Obesity 2014; 22: 1821-1829
- 27 Ntambi JM, Miyazaki M. Recent insights into stearoyl-CoA desaturase-1. Curr Opin Lipidol 2003; 14: 255-261
- 28 Castro LF, Lopes-Marques M, Wilson JM, Rocha E, Reis-Henriques MA, Santos MM, Cunha I. A novel Acetyl-CoA synthetase short-chain subfamily member 1 (Acss1) gene indicates a dynamic history of paralogue retention and loss in vertebrates. Gene 2012; 497: 249-255
- 29 Glatz JF, van der Vusse GJ. Cellular fatty acid-binding proteins: their function and physiological significance. Prog Lipid Res 1996; 35: 243-282
- 30 Ricquier D, Bouillaud F. The uncoupling protein homologues: UCP1, UCP2, UCP3, StUCP and AtUCP. Biochem J 2000; 345 Pt 2 161-179
- 31 Hou Y, Xue P, Bai Y, Liu D, Woods CG, Yarborough K, Fu J, Zhang Q, Sun G, Collins S, Chan JY, Yamamoto M, Andersen ME, Pi J. Nuclear factor erythroid-derived factor 2-related factor 2 regulates transcription of CCAAT/enhancer-binding protein beta during adipogenesis. Free Radical Biol Med 2012; 52: 462-472
- 32 Balaban S, Lee LS, Schreuder M, Hoy AJ. Obesity and cancer progression: is there a role of fatty acid metabolism?. BioMed Res Int 2015; 274585
- 33 Sanders PM, Tisdale MJ. Effect of zinc-alpha2-glycoprotein (ZAG) on expression of uncoupling proteins in skeletal muscle and adipose tissue. Cancer Lett 2004; 212: 71-81
- 34 Robidoux J, Martin TL, Collins S. Beta-adrenergic receptors and regulation of energy expenditure: A family affair. Ann Rev Pharmacol Toxicol 2004; 44: 297-323
- 35 Collins S, Sarzani R, Bordicchia M. Coordinate control of adipose ‘browning’ and energy expenditure by β-adrenergic and natriuretic peptide signalling. Int J Obes Suppl 2014; 4: S17-S20
- 36 Coman OA, Paunescu H, Ghita I, Coman L, Badararu A, Fulga I. Beta 3 adrenergic receptors: Molecular, histological, functional and pharmacological approaches. Roman J Morphol Embryol 2009; 50: 169-179
- 37 Russell ST, Tisdale MJ. Role of β-adrenergic receptors in the anti-obesity and anti-diabetic effects of zinc-α2-glycoprotien (ZAG). Biochim Biophys Acta 2012; 1821: 590-599
- 38 Russell ST, Tisdale MJ. Role of β-Adrenergic Receptors in the Oral Activity of Zinc-α2-Glycoprotein (ZAG). Endocrinology 2012; 153: 4696-4704
- 39 Wargent ET, O’Dowd JF, Zaibi MS, Gao D, Bing C, Trayhurn P, Cawthorne MA, Arch JR, Stocker CJ. Contrasts between the effects of zinc-alpha2-glycoprotein, a putative beta3/2-adrenoceptor agonist and the beta3/2-adrenoceptor agonist BRL35135 in C57Bl/6 (ob/ob) mice. J Endocrinol 2013; 216: 157-168